Overview

Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia

Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
Purpose of the study is to determine if Cimzia is safe and effective in subjects who have received previous treatment with a TNF-alpha inhibitor other than Cimzia.
Phase:
Phase 4
Details
Lead Sponsor:
Michael Schiff, MD
Collaborator:
UCB Pharma
Treatments:
Certolizumab Pegol